Summary
158.25 0.29(0.18%)06/28/2024
Sarepta Therapeutics Inc (SRPT)
Sarepta Therapeutics Inc (SRPT)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 0.18 | 27.98 | 39.55 | 21.46 | 63.16 | 48.52 | 21.78 | 305.19 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 158.25 | |
| Open | 157.96 | |
| High | 159.77 | |
| Low | 156.14 | |
| Volume | 734,627 | |
| Change | 0.29 | |
| Change % | 0.18 | |
| Avg Volume (20 Days) | 2,125,875 | |
| Volume/Avg Volume (20 Days) Ratio | 0.35 | |
| 52 Week Range | 55.25 - 173.25 | |
| Price vs 52 Week High | -8.66% | |
| Price vs 52 Week Low | 186.42% | |
| Range | 0.83 | |
| Gap Up/Down | -1.12 | |
Fundamentals | ||
| Market Capitalization (Mln) | 14,931 | |
| EBIDTA | -52,995,000 | |
| PE Ratio | 309.9767 | |
| PEG Ratio | 159.2500 | |
| WallStreet Target Price | 166.36 | |
| Book Value | 10.1720 | |
| Earnings Per Share | 0.4300 | |
| EPS Estimate Current Quarter | -0.0700 | |
| EPS Estimate Next Quarter | -0.1300 | |
| EPS Estimate Current Year | 3.3900 | |
| EPS Estimate Next Year | 10.8000 | |
| Diluted EPS (TTM) | 0.4300 | |
| Revenues | ||
| Profit Marging | 0.0120 | |
| Operating Marging (TTM) | 0.0844 | |
| Return on asset (TTM) | -0.0189 | |
| Return on equity (TTM) | 0.0202 | |
| Revenue TTM | 1,403,299,968 | |
| Revenue per share TTM | 14.9530 | |
| Quarterly Revenue Growth (YOY) | 0.6310 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | -78,066,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 309.9767 | |
| Forward PE | 35.2113 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 13.4295 | |
| Revenue Enterprise Value | 9.0571 | |
| EBITDA Enterprise Value | -24.8209 | |
| Shares | ||
| Shares Outstanding | 94,523,800 | |
| Shares Float | 90,357,158 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.05 | |
| Insider (%) | 4.40 | |
| Institutions (%) | 87.02 | |
06/26 10:06 EST - fool.com
Is Pfizer's Pain Sarepta Therapeutics' Gain? Don't Bet on It.
Pfizer just whiffed one of its late-stage clinical trials. Sarepta Therapeutics just got regulators to sign off on a similar program.
Is Pfizer's Pain Sarepta Therapeutics' Gain? Don't Bet on It.
Pfizer just whiffed one of its late-stage clinical trials. Sarepta Therapeutics just got regulators to sign off on a similar program.
06/25 09:00 EST - forbes.com
Will Elevidys Approval Make Sarepta Stock An Acquisition Target?
The stock price of Sarepta Therapeutics, a biotech company focused on the discovery and development of RNA-targeted therapeutics and gene therapy for the treatment of rare diseases, was up 30% on Friday, June 21. This move came after the company secured the U.S. FDA approval for its Duchenne muscular dystrophy gene therapy – Elevidys – for all patients aged four and older.
Will Elevidys Approval Make Sarepta Stock An Acquisition Target?
The stock price of Sarepta Therapeutics, a biotech company focused on the discovery and development of RNA-targeted therapeutics and gene therapy for the treatment of rare diseases, was up 30% on Friday, June 21. This move came after the company secured the U.S. FDA approval for its Duchenne muscular dystrophy gene therapy – Elevidys – for all patients aged four and older.
06/24 04:50 EST - zacks.com
Sarepta Therapeutics (SRPT) Soars 30.1%: Is Further Upside Left in the Stock?
Sarepta Therapeutics (SRPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Sarepta Therapeutics (SRPT) Soars 30.1%: Is Further Upside Left in the Stock?
Sarepta Therapeutics (SRPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
06/22 06:47 EST - seekingalpha.com
Sarepta Therapeutics: Pushing The Edge And Creating The Horizon
Sarepta Therapeutics excels in rare disease therapies using RNA, gene editing, and gene therapies, with significant revenue growth driven by ELEVIDYS gene therapy approval. Despite missing the primary endpoint, ELEVIDYS hit key secondary endpoints, leading to FDA approval for all DMD patients ages 4 and older. Now with a label that covers roughly 80% of the DMD population, Sarepta is positioned for explosive growth in the DMD market.
Sarepta Therapeutics: Pushing The Edge And Creating The Horizon
Sarepta Therapeutics excels in rare disease therapies using RNA, gene editing, and gene therapies, with significant revenue growth driven by ELEVIDYS gene therapy approval. Despite missing the primary endpoint, ELEVIDYS hit key secondary endpoints, leading to FDA approval for all DMD patients ages 4 and older. Now with a label that covers roughly 80% of the DMD population, Sarepta is positioned for explosive growth in the DMD market.
06/21 19:05 EST - youtube.com
Sarepta CEO on what's next after expanded muscular dystrophy drug approval
Douglas Ingram, Sarepta CEO, joins 'Fast Money' to talk FDA approval of Elevidys and its impact on the company's stock.
Sarepta CEO on what's next after expanded muscular dystrophy drug approval
Douglas Ingram, Sarepta CEO, joins 'Fast Money' to talk FDA approval of Elevidys and its impact on the company's stock.
06/21 17:45 EST - youtube.com
TD Cowen's Ritu Bara talks Sarepta stock skyrocketing on FDA gene therapy approval
Ritu Baral, TD Cowen Sr. Biotechnology Analyst, joins 'Closing Bell Overtime' to talk Sarepta's approval from the FDA for its Duchenne gene therapy and how it drove the stock to its best trading day in a year.
TD Cowen's Ritu Bara talks Sarepta stock skyrocketing on FDA gene therapy approval
Ritu Baral, TD Cowen Sr. Biotechnology Analyst, joins 'Closing Bell Overtime' to talk Sarepta's approval from the FDA for its Duchenne gene therapy and how it drove the stock to its best trading day in a year.
06/21 13:52 EST - benzinga.com
Sarepta's Expanded Approval Unlikely To Influence Novo Holdings' Acquisition of Catalent, But Provides Investor Protection Amid Uncertainty
Shares of Catalent Inc CTLT, which manufactures Elevidys, are trading higher with a strong session volume of 3.6 million compared to an average volume of 1.6 million.
Sarepta's Expanded Approval Unlikely To Influence Novo Holdings' Acquisition of Catalent, But Provides Investor Protection Amid Uncertainty
Shares of Catalent Inc CTLT, which manufactures Elevidys, are trading higher with a strong session volume of 3.6 million compared to an average volume of 1.6 million.
06/21 13:21 EST - businesswire.com
Wall Street Beats to Host Conference Call with Sarepta CEO on Ground-Breaking Expanded Label Approval
SAN DIEGO--(BUSINESS WIRE)--Wall Street Beats is pleased to announce an investor conference call with Doug Ingram, CEO of Sarepta Therapeutics, following the landmark FDA approval expanding the label for ELEVIDYS (delandistrogene moxeparvovec-rokl) to treat Duchenne muscular dystrophy (DMD) patients aged four and above. The call will be hosted by David Maris, a six-time #1 ranked pharma analyst and partner at Wall Street Beats. Maris stated, "Sarepta's expanded label approval for ELEVIDYS is a.
Wall Street Beats to Host Conference Call with Sarepta CEO on Ground-Breaking Expanded Label Approval
SAN DIEGO--(BUSINESS WIRE)--Wall Street Beats is pleased to announce an investor conference call with Doug Ingram, CEO of Sarepta Therapeutics, following the landmark FDA approval expanding the label for ELEVIDYS (delandistrogene moxeparvovec-rokl) to treat Duchenne muscular dystrophy (DMD) patients aged four and above. The call will be hosted by David Maris, a six-time #1 ranked pharma analyst and partner at Wall Street Beats. Maris stated, "Sarepta's expanded label approval for ELEVIDYS is a.
06/21 12:29 EST - investors.com
Sarepta Stock Surges On FDA News; Industrial Stock In Buy Zone
This biotech stock surged after one of its gene therapies was approved by the Food and Drug Administration.
Sarepta Stock Surges On FDA News; Industrial Stock In Buy Zone
This biotech stock surged after one of its gene therapies was approved by the Food and Drug Administration.
06/21 12:25 EST - zacks.com
FDA Expands Sarepta's (SRPT) DMD Gene Therapy Label
Following the label expansion, Sarepta's (SRPT) Elevidys is approved to treat all DMD patients aged four years and older, regardless of ambulation status.
FDA Expands Sarepta's (SRPT) DMD Gene Therapy Label
Following the label expansion, Sarepta's (SRPT) Elevidys is approved to treat all DMD patients aged four years and older, regardless of ambulation status.
06/21 12:14 EST - youtube.com
Sarepta (SRPT) Soars on FDA Approval on Muscular Dystrophy Treatment
Sarepta (SRPT) soars after the FDA approves expanded use of their Muscular Dystrophy treatment. Jenny Horne weighs in on this story.
Sarepta (SRPT) Soars on FDA Approval on Muscular Dystrophy Treatment
Sarepta (SRPT) soars after the FDA approves expanded use of their Muscular Dystrophy treatment. Jenny Horne weighs in on this story.
06/21 12:06 EST - marketbeat.com
Sarepta Therapeutics Stock Soars on FDA Approval
Sarepta Therapeutics NASDAQ: SRPT is leading the game in precision genetic medicine and biotechnology. Sarepta Therapeutics' stock price has witnessed a surge of over 40% after receiving expanded FDA approval for its Duchenne muscular dystrophy (DMD) gene therapy, Elevidys.
Sarepta Therapeutics Stock Soars on FDA Approval
Sarepta Therapeutics NASDAQ: SRPT is leading the game in precision genetic medicine and biotechnology. Sarepta Therapeutics' stock price has witnessed a surge of over 40% after receiving expanded FDA approval for its Duchenne muscular dystrophy (DMD) gene therapy, Elevidys.
06/21 10:10 EST - youtube.com
Sarepta Soars on Expanded Approval for Muscular Dystrophy Drug
Sarepta Therapeutics' gene therapy received expanded US approval to include more children with a deadly muscle disease. The treatment's approval was widened for use in patients who are at least 4 years old with Duchenne muscular dystrophy.
Sarepta Soars on Expanded Approval for Muscular Dystrophy Drug
Sarepta Therapeutics' gene therapy received expanded US approval to include more children with a deadly muscle disease. The treatment's approval was widened for use in patients who are at least 4 years old with Duchenne muscular dystrophy.
06/21 10:05 EST - proactiveinvestors.com
Sarepta Therapeutics shares surge as muscular dystrophy therapy approved for expanded use
Sarepta Therapeutics Inc (NASDAQ:SRPT) shares soared almost 35% after the US Food and Drug Administration (FDA) approved the expanded use of its gene therapy Elevidys for patients with Duchenne muscular dystrophy (DMD). DMD is a rare genetic condition which causes weakness and the wasting away of the body's muscles, with symptoms including trouble walking and running, falling frequently, fatigue and learning disabilities or difficulties.
Sarepta Therapeutics shares surge as muscular dystrophy therapy approved for expanded use
Sarepta Therapeutics Inc (NASDAQ:SRPT) shares soared almost 35% after the US Food and Drug Administration (FDA) approved the expanded use of its gene therapy Elevidys for patients with Duchenne muscular dystrophy (DMD). DMD is a rare genetic condition which causes weakness and the wasting away of the body's muscles, with symptoms including trouble walking and running, falling frequently, fatigue and learning disabilities or difficulties.
06/21 09:32 EST - investorplace.com
Sarepta Therapeutics (SRPT) Stock Surges 30% on Giant FDA Boost
Sarepta Therapeutics (NASDAQ: SRPT ) stock jumped about 30% overnight after the Food and Drug Administration (FDA) approved one of its gene therapies for children with Duchenne muscular dystrophy (DMD). Peter Marks, director of the Center for Biologics Evaluation and Research, overruled three research teams and his top lieutenants in making the decision.
Sarepta Therapeutics (SRPT) Stock Surges 30% on Giant FDA Boost
Sarepta Therapeutics (NASDAQ: SRPT ) stock jumped about 30% overnight after the Food and Drug Administration (FDA) approved one of its gene therapies for children with Duchenne muscular dystrophy (DMD). Peter Marks, director of the Center for Biologics Evaluation and Research, overruled three research teams and his top lieutenants in making the decision.
06/21 09:31 EST - investopedia.com
Sarepta Therapeutics Soars on Expanded Approval for Its Muscular Dystrophy Drug
Sarepta Therapeutics (SRPT) shares soared in premarket trading Friday, a day after the Food and Drug Administration (FDA) allowed expanded use of the biotech's treatment for a rare muscle disease in children, which especially affects boys.
Sarepta Therapeutics Soars on Expanded Approval for Its Muscular Dystrophy Drug
Sarepta Therapeutics (SRPT) shares soared in premarket trading Friday, a day after the Food and Drug Administration (FDA) allowed expanded use of the biotech's treatment for a rare muscle disease in children, which especially affects boys.
06/21 08:05 EST - marketwatch.com
Sarepta Therapeutics' stock soars 38% after FDA expands use of its Duchenne muscular-dystrophy drug
Sarepeta Therapeutics Inc.'s stock soared 38% in premarket trade Friday, after the biotech said the U.S. regulator has approved an expanded indication of its treatment for the rare muscle disorder Duchenne muscular dystrophy.
Sarepta Therapeutics' stock soars 38% after FDA expands use of its Duchenne muscular-dystrophy drug
Sarepeta Therapeutics Inc.'s stock soared 38% in premarket trade Friday, after the biotech said the U.S. regulator has approved an expanded indication of its treatment for the rare muscle disorder Duchenne muscular dystrophy.
06/21 07:43 EST - barrons.com
Sarepta Stock Surges on Expanded Approval for Elevidys. What Wall Street Thinks.
The biopharmaceutical company says the drug was approved for ambulatory and non-ambulatory people, who are at least 4 years old, and with a confirmed mutation in the DMD gene.
Sarepta Stock Surges on Expanded Approval for Elevidys. What Wall Street Thinks.
The biopharmaceutical company says the drug was approved for ambulatory and non-ambulatory people, who are at least 4 years old, and with a confirmed mutation in the DMD gene.
06/21 07:39 EST - benzinga.com
FDA Approves Expanded Use For Sarepta's Rare Muscular Dystrophy Gene Therapy
Thursday, the FDA approved labeled indication for Sarepta Therapeutics Inc's SRPT Elevidys (delandistrogene moxeparvovec-rokl) to include individuals with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene who are at least 4 years of age.
FDA Approves Expanded Use For Sarepta's Rare Muscular Dystrophy Gene Therapy
Thursday, the FDA approved labeled indication for Sarepta Therapeutics Inc's SRPT Elevidys (delandistrogene moxeparvovec-rokl) to include individuals with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene who are at least 4 years of age.
06/21 06:53 EST - reuters.com
Sarepta surges as investors cheer expanded use of gene therapy
Sarepta Therapeutics shares surged about 36% in premarket trading on Friday as an expanded use approval opened up a bigger market in the U.S. for its gene therapy for patients with Duchenne muscular dystrophy (DMD).
Sarepta surges as investors cheer expanded use of gene therapy
Sarepta Therapeutics shares surged about 36% in premarket trading on Friday as an expanded use approval opened up a bigger market in the U.S. for its gene therapy for patients with Duchenne muscular dystrophy (DMD).